Published in Oncotarget on September 15, 2014
Principles of allosteric interactions in cell signaling. J Am Chem Soc (2014) 0.97
A New View of Ras Isoforms in Cancers. Cancer Res (2015) 0.90
The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B. Sci Rep (2016) 0.83
Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation. Cancer Res (2015) 0.79
A network-based method to evaluate quality of reproducibility of differential expression in cancer genomics studies. Oncotarget (2015) 0.75
Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. Cancer Inform (2016) 0.75
Advancements and challenges in computational biology. PLoS Comput Biol (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Cancer genome landscapes. Science (2013) 25.33
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Funnels, pathways, and the energy landscape of protein folding: a synthesis. Proteins (1995) 14.36
Clonal evolution in cancer. Nature (2012) 11.07
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science (1997) 9.21
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
A dimerization-dependent mechanism drives RAF catalytic activation. Nature (2009) 5.39
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res (2002) 4.98
Nonlinear elasticity, proteinquakes, and the energy landscapes of functional transitions in proteins. Proc Natl Acad Sci U S A (2003) 4.36
The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer (2013) 4.20
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02
A comprehensive survey of Ras mutations in cancer. Cancer Res (2012) 3.67
Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature (2010) 3.52
Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 3.45
Dragging ras back in the ring. Cancer Cell (2014) 3.10
Chromosome aberrations and cancer. Science (1991) 3.00
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet (2013) 2.83
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell (2012) 2.67
Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther (2013) 2.64
Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol (2012) 2.56
Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem (1996) 2.43
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev (2010) 2.27
The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem (2009) 2.23
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer (2013) 2.17
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A (2013) 2.15
End-joining, translocations and cancer. Nat Rev Cancer (2013) 2.13
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet (2008) 2.05
The genetic basis for cancer treatment decisions. Cell (2012) 2.03
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther (1999) 1.96
Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat Protoc (2011) 1.84
Chromosomal abnormalities in cancer. N Engl J Med (2008) 1.81
Interpreting the language of histone and DNA modifications. Biochim Biophys Acta (2014) 1.80
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer (2013) 1.80
Allostery in disease and in drug discovery. Cell (2013) 1.77
Matching targets for selective cancer therapy. Drug Discov Today (2003) 1.75
K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res (2000) 1.73
Simultaneous identification of multiple driver pathways in cancer. PLoS Comput Biol (2013) 1.71
Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci U S A (2010) 1.62
A unified view of "how allostery works". PLoS Comput Biol (2014) 1.59
Dynamic allostery: linkers are not merely flexible. Structure (2011) 1.58
Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med (2013) 1.46
Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol (2011) 1.43
Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep (2005) 1.43
What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. J Genet Couns (2010) 1.41
The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal (2010) 1.39
Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A (2013) 1.35
"Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle (2008) 1.34
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics (2008) 1.31
Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. Proc Natl Acad Sci U S A (2014) 1.31
Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med (2014) 1.31
The metastatic niche and stromal progression. Cancer Metastasis Rev (2012) 1.30
Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel (2010) 1.28
Contribution of p53 to metastasis. Cancer Discov (2014) 1.28
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood (2004) 1.28
From bytes to bedside: data integration and computational biology for translational cancer research. PLoS Comput Biol (2007) 1.27
Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol (2013) 1.26
PRISM: a web server and repository for prediction of protein-protein interactions and modeling their 3D complexes. Nucleic Acids Res (2014) 1.26
The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets (2003) 1.26
The roots of bioinformatics in theoretical biology. PLoS Comput Biol (2011) 1.24
H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc Natl Acad Sci U S A (2014) 1.23
Protein frustratometer: a tool to localize energetic frustration in protein molecules. Nucleic Acids Res (2012) 1.23
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 1.22
VarWalker: personalized mutation network analysis of putative cancer genes from next-generation sequencing data. PLoS Comput Biol (2014) 1.20
Improving breast cancer survival analysis through competition-based multidimensional modeling. PLoS Comput Biol (2013) 1.20
Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. Proc Natl Acad Sci U S A (2008) 1.20
PI3Kα inhibitors that inhibit metastasis. Oncotarget (2010) 1.19
Allo-network drugs: harnessing allostery in cellular networks. Trends Pharmacol Sci (2011) 1.17
Antigen selection in B-cell lymphomas--tracing the evidence. Semin Cancer Biol (2013) 1.16
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood (1993) 1.14
The underappreciated role of allostery in the cellular network. Annu Rev Biophys (2013) 1.12
Bcr-Abl variants: biological and clinical aspects. Leuk Res (2002) 1.11
A second molecular biology revolution? The energy landscapes of biomolecular function. Phys Chem Chem Phys (2014) 1.10
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol (2013) 1.10
The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget (2013) 1.09
Fusion genes in solid tumors. Semin Cancer Biol (1999) 1.08
Constructing structural networks of signaling pathways on the proteome scale. Curr Opin Struct Biol (2012) 1.07
The mechanism of ubiquitination in the cullin-RING E3 ligase machinery: conformational control of substrate orientation. PLoS Comput Biol (2009) 1.05
Free energy profile of H-ras membrane anchor upon membrane insertion. Angew Chem Int Ed Engl (2007) 1.04
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure (2012) 1.04
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget (2014) 1.03
Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. Oncotarget (2013) 1.03
Modular evolution of phosphorylation-based signalling systems. Philos Trans R Soc Lond B Biol Sci (2012) 1.02
The structural network of Interleukin-10 and its implications in inflammation and cancer. BMC Genomics (2014) 1.02
A mechanism for the auto-inhibition of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel opening and its relief by cAMP. J Biol Chem (2014) 1.01